4.5 Review

Fragment-Based Drug Discovery for RNA Targets

期刊

CHEMMEDCHEM
卷 16, 期 17, 页码 2588-2603

出版社

WILEY-V C H VERLAG GMBH
DOI: 10.1002/cmdc.202100324

关键词

drug discovery; fragments; RNA; screening

资金

  1. Novo Nordisk Foundation [NNF19OC0055818]
  2. Carlsberg Foundation [CF19-0072, CF17-0795]
  3. DTU
  4. Ministry of Higher Education and Science [5072-00019B]
  5. Villum Foundation [00007303]
  6. Technion
  7. Research Council of Norway
  8. Joint Programming Initiative on Antimicrobial Resistance, JPIAMR (Explore) [297192, 261961, 294594]

向作者/读者索取更多资源

The rapid development in fragment-based drug discovery and medicinal targeting of RNA has opened up possibilities for combining technologies and methods in novel ways. This review discusses the use of fragment-based screening against RNA targets, including the latest screening and hit validation methods, and provides insights on future perspectives in this field.
Rapid development within the fields of both fragment-based drug discovery (FBDD) and medicinal targeting of RNA provides possibilities for combining technologies and methods in novel ways. This review provides an overview of fragment-based screening (FBS) against RNA targets, including a discussion of the most recently used screening and hit validation methods such as NMR spectroscopy, X-ray crystallography, and virtual screening methods. A discussion of fragment library design based on research from small-molecule RNA binders provides an overview on both the currently limited guidelines within RNA-targeting fragment library design, and future possibilities. Finally, future perspectives are provided on screening and hit validation methods not yet used in combination with both fragment screening and RNA targets.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据